echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Stroke: Effects of Cilostazol and Aspirin on White Matter Changes in Cerebral Small Vessel Diseases

    Stroke: Effects of Cilostazol and Aspirin on White Matter Changes in Cerebral Small Vessel Diseases

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cerebral small vessel wherein the disease is a progressive change in the white matter (the WMC)
    .

    Blood vessel

    Recently, a research article was published in Stroke, an authoritative journal in the field of cardiovascular diseases, which aims to compare the effects of cilostazol and aspirin on the changes of WMC volume in patients with cerebral small vessel disease
    .

    Cardiovascular

    In this multi-center, double-blind, randomized controlled trial, participants with moderate or severe WMC and at least one lacunar infarction detected on a brain magnetic resonance imaging examination were randomly assigned to the West at a 1:1 ratio.
    Lostazol group and aspirin group
    .


    The subjects took cilostazol sustained-release capsules (200 mg) or aspirin (100 mg) capsules once a day for 2 years


    Stroke

    Between July 2013 and August 2016, 256 participants were randomly assigned to the cilostazol (n=127) group and aspirin (n=129) group
    .


    Over the past two years, the percentage of WMC volume in the total WM volume and the percentage of WMC volume in the intracranial volume of the two groups of subjects have both increased, but neither analysis showed a significant difference between the groups


    It can be seen that there is no significant difference in the effects of cilostazol and aspirin on the progression of WMC in patients with cerebral small vessel disease
    .

    There was no significant difference in the effects of cilostazol and aspirin on the progression of WMC in patients with cerebral small vessel disease
    .


    Original source:

    Original source:

    Byeong C.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.